Business Context and Reporting Period
This Form 8-K filing by Actinium Pharmaceuticals, Inc. (the "Company") reports a corporate merger event dated September 25, 2013. The Company merged its 93.7% owned subsidiary, Actinium Corporation, into itself, resulting in the cessation of Actinium Corporation as a separate legal entity.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structural details of the merger and the issuance of equity securities.
Material Changes
- Merger Completion: Actinium Corporation was merged into Actinium Pharmaceuticals, Inc. on September 25, 2013.
- Equity Exchange: Each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.
- Share Issuance: A total of 3,970,137 shares of Actinium Corporation common stock were exchanged for 1,322,055 shares of Company common stock.
- Ownership Status: As of September 30, 2013, the Company acquired 100% of the issued and outstanding equity securities of Actinium Corporation (totaling 63,018,053 shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It notes that the shares issued to former shareholders of Actinium Corporation were sold in a private transaction relying on exemptions from registration under Section 4(2) of the Securities Act, Rule 506 of Regulation D, and Regulation S. The Company determined these investors were "accredited investors" based on their representations.
Investor Verification Checklist
- Verify the exact number of new shares issued (1,322,055) and the resulting total share count of the Company.
- Confirm the 0.333 exchange ratio applied to non-owned Actinium Corporation shares.
- Review the Company's subsequent filings (e.g., 10-Q or 10-K) for the consolidated financial impact of the merger.
- Ensure the "accredited investor" status of recipients was properly documented to validate the Regulation D exemption.